Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,473 total articles
Archer-Daniels-Midland (ADM) trades like a cash-generative industrial with modest leverage and a growing exposure to higher-margin protein and specialty ingredients. Near-term technical weakness and elevated short activity have opened a tactical entry around $77.50. Target $86 on a 45-trading-day horizon, stop $73. Trade thesis: ADM's diversified p…
Cenovus (CVE) combines upstream oil exposure with a meaningful downstream franchise. Technicals and price action show momentum while valuation remains reasonable for an energy name, giving traders an asymmetric risk/reward to stay long through the next market leg. This trade lays out entry, stop and target levels with a mid-term time frame and a cl…
Standard Lithium is approaching Final Investment Decision for its South West Arkansas project after a binding offtake with Trafigura and more than $1 billion in debt indications of interest. With a market cap of roughly $621M and recent technicals supportive, this is a tactical long for a mid-term swing that targets a re-rating around prior equity …
Digi International (DGII) reported record recurring revenue and accelerating top-line growth after a string of accretive acquisitions. Fundamentals and free cash flow support a constructive view, while valuation still leaves room for multiple expansion if software/subscription growth persists. This trade idea targets a move back toward the 52-week …
Marvell (MRVL) is expensive on headline multiples, but the company's accelerating AI-custom silicon, optics, and shared-memory roadmap plus strategic commercial deals create a clear path to justify a higher valuation. This trade idea lays out a mid-term (45 trading days) long entry at $227.81 with a $330 target and a $195 stop—a disciplined way to …
Salesforce is pairing a blistering $27B single-quarter buyback with rapidly scaling AI monetization to compress supply and drive EPS higher. The business still generates strong free cash flow ($14.66B) and trades below its 52-week high, presenting a mid-term trade opportunity. This idea lays out an entry at $211.32, a stop at $185.00, and a $250.00…
Coinbase's recent bounce looks sustainable, not a dead cat. With a market cap near $49.5B, $COIN is trading on improving volume, bullish momentum and several near-term catalysts — most importantly a Senate vote on crypto clarity on 09/15/2026. We lay out a mid-term trade (45 trading days) with entry, stop and target, plus the risks and what would c…
KE Holdings (BEKE) looks poised to inflect higher after a string of operational improvements, cash returns and recent earnings beats. With a market cap near $19.7B, a healthy cash cushion, rising buybacks and signs of margin recovery, we upgrade to a tactical long and lay out a 180-trading-day plan: entry $17.80, target $20.50, stop $16.50.
Perma-Pipe (PPIH) is trading around $26.67 with a market cap near $224M, a PE ~16 and EV/EBITDA ~7.4. Recent operational wins and a growing backlog underpin upside, while the share base and conservative leverage limit downside. This trade idea buys a measured dip for a long-term swing toward $34 with a tight stop below $24.
Copart (CPRT) has been punished for a string of governance headlines and a quarterly miss, but the core business still converts to free cash flow at scale. With $1.34B in free cash flow, no net leverage and a P/E near 20, the stock looks positioned to retest and ultimately exceed prior highs if operational execution stabilizes and the legal/managem…
Borr Drilling's management recently increased direct ownership via option exercises and activity from institutional buyers is visible. The stock trades at a market cap of roughly $1.35B with a 52-week range of $2.44-$6.66. Technicals show bullish momentum and short interest has risen, setting up a tradeable long with clear entry, target and stop le…
People Incorporated's accumulation and a non-binding $48.30 per-share offer have materially changed the risk/reward for MGM Resorts. With a $11.06B market cap, $1.49B of free cash flow, and an enterprise value of $14.6B, MGM looks attractively priced even before a potential bidding auction. We upgrade to Buy and lay out a mid-term swing trade with …
Apple is trading near $312.56 after a recent run; with Berkshire Hathaway and other large holders showing renewed appetite for tech, Apple looks like a pragmatic buy. Valuation is rich on headline multiples but supported by exceptional cash generation, high ROE and steady buyback/dividend policy. This trade proposes a disciplined entry at $312.56, …
Rocket Lab (RKLB) checks many growth-boxes but trades at a sky-high valuation (roughly 60x trailing sales) while remaining unprofitable and reliant on the unflown Neutron rocket. This trade idea outlines a mid-term short looking to exploit execution and multiple compression risk ahead of key milestones.
Power Solutions International (PSIX) has recovered sharply from its late-July lows after Q2 developments and sits at a valuation that looks reasonable relative to its cash generation and profitability. The balance sheet and free cash flow profile give a buffer, while elevated short interest and ongoing legal scrutiny argue for a defined risk plan. …
Novo Nordisk is trading at a valuation that looks unusually cheap for a global leader in diabetes and obesity care. Recent legal wins, a raised full-year outlook and a still-healthy cash-generating core argue for a tactical long. This trade idea gives an entry, stop and target with horizon and risk framing.
Sanofi's fundamentals and pipeline momentum make it resilient to headline risk from vaccine-policy debate. Recent results show broad-based growth and an upgraded 2026 outlook; the trade idea is a mid-term long with an entry at $45.40, a stop at $43.00 and a target at $52.00 (45 trading days).
AVITA's RECELL platform is showing real-world evidence of shorter hospital stays and better healing that should appeal to payers. With a market cap near $300M and recent momentum, a measured long trade targets a re-rate as reimbursement improves. Key risks include legacy reimbursement backlogs, weak liquidity and elevated short interest.
Prenetics has converted early R&D and genomics credibility into a direct-to-consumer consumer health engine with IM8. A $1 billion growth financing led by General Catalyst's CVF, a $70 million cash injection from the Insighta sale, zero debt and $171.1 million in adjusted liquidity create a rare combination: aggressive marketing capacity with a cle…
Harmony Gold (HMY) is a core gold exposure with a growing copper footprint and attractive cashflow characteristics as gold prices stay elevated. At $23.54 and a $14.8B market cap, the stock shows bullish technicals and improving liquidity. Reaffirm Buy with a clear entry at $23.54, stop at $19.00 and primary target at $29.00, horizon mid-term (45 t…
Royal Gold has leaned into growth while keeping leverage minimal. At $261 today, the company offers diversified exposure to gold, silver and copper without mine-level execution risk. With a market cap near $22B, low debt, steady EPS, and dividend growth, RGLD is a tactical long for investors who want leverage to metals with an income kicker and dow…
Generac (GNRC) has shifted from a cyclical residential story toward commercial and industrial and data-center power solutions. Recent results and a large hyperscaler supply deal have reignited revenue growth and earnings beats. Valuation is not cheap, but improving fundamentals and supportive technicals set up a mid-term swing trade with defined ri…
Deutsche Post DHL (ticker DPDGY) has shifted from a legacy postal utility to a higher-quality logistics platform. Operational improvements, disciplined pricing in parcel markets, and network investments justify paying up relative to the old business. This trade targets a near-term entry and a multi-horizon upside while balancing execution and macro…
Halozyme is no longer a small-platform play. With guidance pointing to $1.71-$1.81B in 2026 revenue, royalty streams topping $1B, robust free cash flow, and an opportunistic $300M acquisition, the company looks positioned to compound value into 2027. Technicals are hot, so the trade recommends a disciplined long entry with a clear stop and a pragma…
Sika manufactures specialty chemicals and systems that increase the effective materials content per construction project. With steady end-market fundamentals, price and mix levers, and a track record of share gains, Sika sets up as a compounder inside a construction cycle. This trade idea outlines an actionable long entry, stop, and target, framed …
